1Ten Care H. Pathophysiology of disseminated intravaseular coagulation in sepsis[J]. Crit Care Med, 2000,28(9supple):S9 -S11.
2Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients[J]. Lancet, 2001,357: 1096 - 1097.
3Yan SB, Heherbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcomes in severe sepsis [ J ]. Chest, 2001,120:915 -922.
4Warren BL, Eid A, Singer P, et al. Caring for the critically ill patirnts. High-dose antithrombin Ⅲ in severe sepsis: A randomized controlled trial[ J]. JAMA, 2001,286: 1869 - 1578.
5Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis [ J ]. New Engl J Med, 2001,344(10) : 699 -709.
6Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics and ppharmacodynamics of drotrecogin alfa ( activated ) in children with severe sepsis [ J ]. Pediatrics, 2004,113 ( 1 Pt 1 ) : 7 - 17.
7Abraham E, Reinhart K, Svoboda P,et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A muhicenter, randomized, placebo-controlled, single- blind, dose escalation study [ J ]. Crit Care Med, 2001,29 ( 11 ) : 2081 - 2089.
8Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of recombinant tifacogin ( tissue factor pathway inhibitor) in severe sepsis [ J ]. JAMA, 2003,290 ( 2 ): 238 - 247.
